← Search & browse all drugs
CARDIOVASCULAR SYSTEM › CALCIUM CHANNEL BLOCKERS › SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS › Dihydropyridine derivatives
lacidipine
C08CA09
Forms & Strengths
- Tablets: 2mg, 4mg, 6mg
- Extended-release tablets: 2mg, 4mg, 6mg, 8mg
Adult Dosing
- Initial dose: 2mg-4mg once daily
- Maintenance dose: 4mg-6mg once daily
- Maximum dose: 6mg once daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Not recommended for patients under 18 years old
Indications
- Hypertension
- Angina pectoris
- Raynaud's phenomenon
Mechanism of Action
- Selective L-type calcium channel blocker
- Inhibits calcium influx into vascular smooth muscle and cardiac muscle
- Dilates peripheral arteries and reduces peripheral resistance
Contraindications
- Hypersensitivity to lacidipine or other dihydropyridines
- Severe aortic stenosis
- Unstable angina
- Acute myocardial infarction
Adverse Reactions
- Edema
- Headache
- Dizziness
- Flushing
- Palpitations
- Gastrointestinal upset
Drug Interactions
- CYP3A4 inhibitors (e.g. ketoconazole, grapefruit juice) increase lacidipine plasma levels
- CYP3A4 inducers (e.g. rifampicin) decrease lacidipine plasma levels
- Concomitant use with beta blockers or digoxin may increase risk of bradycardia or AV block
Curated Content: Needs Vetting Before Put to Clinical Use